| Filed On | Filing |
|---|---|
| 02 Oct 2026 |
8-K: Other Events
BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular e... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 01 Jul 2026 |
Form 4: Barton Shane, Principal Accounting Officer
Received 39,718 shares by exercise or conversion ($263K) · Sold 42,350 shares ($1.07M) · Received 20,216 shares by exercise or conversion ($132K) · 1 more |
| 30 Jun 2026 | 144 |
| 29 Jun 2026 | 144 |
| 12 Jun 2026 |
Form 4: Pande Vijay Satyanand, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Hemrajani Rekha, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Healy James, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Enright Patrick G, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Davidson Michael H., Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Garnier Jean Pierre, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 08 May 2026 | 10-Q |
| 08 May 2026 | 8-K: Results of Operations and Financial Condition |
| 27 Apr 2026 | SCHEDULE 13G |
| 24 Apr 2026 |
Form 4: Goldstein Dov A Md, Chief Financial Officer
Received 3,542 shares by exercise or conversion ($15.5K) |
Loading...
